1. Home
  2. Press release
Nov 30, 2020 14:04 JST

Source: Eisai

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting

TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa), at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.

A total of 43 poster presentations regarding perampanel are planned, including analysis results from the phase III clinical trial (FREEDOM/Study 342), which evaluated the effectiveness and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with partial onset seizures (POS) from 12 to 74 years of age without prior treatment history. Additionally, results from the phase III clinical trial Study 311 evaluating safety and tolerability of perampanel as an adjunctive therapy in pediatric epilepsy patients with POS or primary generalized tonic clonic (PGTC) seizures from 4 to less than 12 years of age will be presented.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. In Japan and the United States, perampanel is currently approved for monotherapy and adjunctive use in the treatment of POS (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older, as well as adjunctive treatment for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. As we provide perampanel globally, Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai seeks to address the diverse needs of, as well as increase the benefits provided to, patients with epilepsy and their families.

For more information, visit https://www.eisai.com/news/2020/pdf/enews202080pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
 
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
 
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
 
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
 
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
 
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
 
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
 
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
 
More Press release >>

Latest Press Release


Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 21, 2026 20:52 JST

Hitachi to establish a new company with Nojima under a strategic partnership to accelerate growth of its home appliance business
Apr 21, 2026 19:21 JST

BULL and Fujitsu Sign Basic Agreement to Develop Japan's Unique High-Precision Space Situational Awareness Service
Apr 21, 2026 11:47 JST

Fujitsu launches GLOVIA One ERP solution for mid-sized Japanese enterprises
Apr 20, 2026 11:46 JST

NEC to Supply Nine Types of Defense Equipment for Tthree Australian Frigates
Apr 19, 2026 12:10 JST

Mitani Sangyo Filed U.S. Patent Application for AI Reliability Governance Framework
Apr 17, 2026 00:00 JST

TANAKA PRECIOUS METAL NEXT Certified as a Special Subsidiary
Apr 16, 2026 21:00 JST

Isuzu and Toyota to Jointly Develop Japan's First Mass-produced Light-duty Fuel Cell Electric Truck
Apr 16, 2026 15:53 JST

Honda to Begin Sales of All-new Insight EV

Apr 16, 2026 15:31 JST

Hitachi Energy and Samsung C&T expand strategic collaboration to accelerate grid infrastructure and reinforce energy security
Apr 15, 2026 18:17 JST

Mitsubishi Motors' Outlander PHEV Ranks No. 1 in Japan's PHEV Sales Category for the Second Consecutive Year
Apr 15, 2026 18:01 JST

DENSO Establishes Strategic Partnership with Oracle to Modernize Core Supply Chain Systems
Apr 15, 2026 11:25 JST

Fujitsu and Chugoku Electric Power T&D sign IP licensing agreement to accelerate renewable energy integration and advance power transmission maintenance
Apr 15, 2026 11:07 JST

Seres Cements Luxury EV Leadership with Record Sales and RMB12.51 Billion R&D Investment
Apr 14, 2026 10:29 JST

Axonex Intelligence' AI Robotics Series Makes a Splash at InnoEX
Apr 13, 2026 19:33 JST

SuperX Japan Global Supply Center Completes First Batch Delivery, Marking Strategic Partnership Milestone in Japan
Apr 13, 2026 16:52 JST

Alpha Growth plc: Alpha Longevity Management launches U.S. specialty finance strategy for Japanese institutional investors, led by former members of Nikko Asset Management's team
Apr 13, 2026 16:00 JST

IFS and NEC to Deploy Next-Generation Core System IFS Cloud for Hoshizaki
Apr 10, 2026 10:10 JST

NEC's Automated Negotiation AI recognized as a Use Case in Gartner(R) Research
Apr 09, 2026 13:41 JST

Mitsubishi Motors Launches the Xforce in Malaysia
Apr 08, 2026 20:47 JST
 More Latest Release >>